These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35394498)

  • 1. A Bacterial-Based Immunotherapy for PDAC.
    Cancer Discov; 2022 Jun; 12(6):OF1. PubMed ID: 35394498
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Selvanesan BC; Chandra D; Quispe-Tintaya W; Jahangir A; Patel A; Meena K; Alves Da Silva RA; Friedman M; Gabor L; Khouri O; Libutti SK; Yuan Z; Li J; Siddiqui S; Beck A; Tesfa L; Koba W; Chuy J; McAuliffe JC; Jafari R; Entenberg D; Wang Y; Condeelis J; DesMarais V; Balachandran V; Zhang X; Lin K; Gravekamp C
    Sci Transl Med; 2022 Mar; 14(637):eabc1600. PubMed ID: 35320003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
    Sahin IH; Askan G; Hu ZI; O'Reilly EM
    Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
    Kieler M; Unseld M; Bianconi D; Prager G
    Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.
    Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF
    Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
    Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
    Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
    Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
    BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling pancreatic cancer in mice for experimental therapeutics.
    Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
    Ye C; Zheng L; Yuan CH
    Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.
    Brouwer TP; Vahrmeijer AL; de Miranda NFCC
    Cell Oncol (Dordr); 2021 Apr; 44(2):261-278. PubMed ID: 33710604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
    Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
    Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.